Document is current
Any future updates will be listed below
-
Authors
Gao, Xin D. https://orcid.org/0000-0003-2917-2060
Presa, Maximiliano
Duby, Jordyn E.
Ryan, Jennifer
Piec, Pierre-Alexandre
Hsu, Alvin https://orcid.org/0000-0003-4034-2788
Banskota, Samagya
Jiang, Allen Yujie https://orcid.org/0000-0002-9826-5976
Chen, Lingxiao
Newby, Gregory A.
Di Pietro, Erminia
Levy, Jonathan M. https://orcid.org/0000-0002-8061-7953
Steele, Bradford H.
Lecordier, Sarah
Qin, Fangfei
Moser, Ann B. https://orcid.org/0000-0002-9147-1902
Xie, Jun https://orcid.org/0000-0001-9565-1567
Gao, Guangping https://orcid.org/0000-0003-0097-9012
Braverman, Nancy E.
Zuberi, Aamir R.
Hacia, Joseph G. https://orcid.org/0000-0002-1481-9282
Lutz, Cathleen M. https://orcid.org/0000-0003-2502-1900
Liu, David R. https://orcid.org/0000-0002-9943-7557
-
Funding
Funding for this research was provided by:
Howard Hughes Medical Institute (Liu investigatorship)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (U01 AI142756)
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (RM1 HG009490)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35 GM118062)
- License Information
-
More Information
Article History
Received: 23 February 2025
Accepted: 6 March 2026
First Online: 14 April 2026
Competing interests
: X.D.G., M.P., J.G.H., C.M.L. and D.R.L. have filed patent applications on this work. D.R.L. is a consultant and/or equity owner of Prime Medicine, Beam Therapeutics, Pairwise Plants, Exo Therapeutics and nChroma Bio, companies that use or deliver genome editing or epigenome-modulating agents. J.M.L. is a current employee of Prime Medicine. X.D.G. is currently an assistant professor at the University of Pittsburgh School of Medicine, S.B. is currently an assistant professor at Boston University, and G.A.N. is currently an assistant professor at the Johns Hopkins University. B.H.S. is a current employee of Genvivo, Inc. The other authors declare no competing interests.
